Abstract:OBJECTIVE:To investigate the relationship between the serum level of vancomycin and its clinical efficacy as well as adverse reactions in adult patient so as to provide recommendations for clinical management.METHODS:An open observational research was performed from 1st July 2013 to 31st December 2017 in Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, which recruited the adult patients who were infected with Gram positive (G+) bacteria and treated with vancomycin. The initial dose was decided by the patient's creatinine clearance rate, and the treating dose was directed by the serum drug concentration and the patient's clinical response. By recording the associated clinical information (pathogen eradication, blood test results, adverse reactions, etc.), the clinical outcome and adverse reactions for vancomycin to treat G+ bacterial infections were analyzed.RESULTS:Eighty-nine cases who meet research standards were finally recruited, with 67.42% of male patients, and an average age of (50.5±17.9) years. The most common type of infection was bloodstream infection (61.80%), followed by low respiratory infection (17.98%). Infections caused by Staphylococcus aureus accounted for 39.33%. The bacterial eradication rate was 89.89% (80/89) and the total effective rate was 77.53% (69/89). The effective rate was 80.30% (53/66) with minimum inhibitory concentration (MIC) < 2 mg/L vs. 69.57% (16/23) with MIC ≥ 2 mg/L, the difference was not statistically significant (χ2 = 1.129, P = 0.288). The effective rate was 72.92% (35/48) with trough levels < 10 mg/L vs. 82.93% (34/41) with trough levels ≥ 10 mg/L, the difference was not statistically significant (χ2 = 1.272, P = 0.259). There were 4 cases of vancomycin associated nephrotoxicity, the incidence of nephrotoxicity was 4.49%, and the vancomycin serum trough levels were 17.22-28.53 mg/L. There were 33 cases of liver dysfunction, and elevated γ-glutamine transferase, alkaline phosphatase and aspartate aminotransferase were most common. There were 2 cases of neutropenia and 2 patients appeared rash during vancomycin period.CONCLUSIONS:Treatment outcomes were similar regardless of vancomycin MIC and serum trough level. The incidence of vancomycin associated nephrotoxicity rises apparently when serum trough level is over 15 mg/L.CLINICAL TRIAL REGISTRY:Chinese Clinical Trail Registry, ChiCTR-OPC-16007920.

Clinical Pharmacokinetics and Therapeutic Drug Monitoring of Norvancomycin

Analysis on therapeutic drug monitoring data of vancomycin in 64 elderly patients

Pharmacokinetics of Norvancomycin of SICU Patients

Population Pharmacokinetic and Pharmacodynamic Modeling of Norvancomycin

Pharmacokinetics of Vancomycin in Elderly and Young Healthy Volunteers

[The Adverse Reactions of Parenteral Norvancomycin in 1031 Patients].

Application of Monte Carlo simulation to optimize the dosage regimen of norvancomycin

Establishment of norvancomycin fluorescence polarization immunoassay for therapeutic drug monitoring

The effect of norvancomycin on the infection of MRS and the evaluation of the bacteriological investigation

Age-Related Differences in Vancomycin-Associated Nephrotoxicity and Efficacy in Methicillin-Resistant Staphylococcus aureus Infection: A Comparative Study between Elderly and Adult Patients

Study on pharmacokinetics and tissue distribution of norvancomycin in rats by CE with electrochemical detection.

Investigation of vancomycin used in geriatric patients

The study on adverse reactions induced by vancomycin or norvancomycin

Clinical Evaluation of a Vancomycin Dosage Strategy Based on a Serum Trough Concentration Model in Elderly Patients with Severe Pneumonia

Evaluation of Norvancomycin in Treatment of MRS Infections

[Monitoring of Vancomycin Serum Concentrations and the Evaluation of Its Safety and Treatment Outcomes in Adult Patients].

Evaluation of the population pharmacokinetic models of vancomycin in geriatric patients

Analysis the relationship between vancomycin serum concentration and nephrotoxicity or clinical efficiency

Determination of Vancomycin and Norvancomycin in human serum by HPLC

Population Pharmacokinetics of Vancomycin and Prediction of Pharmacodynamics in the Chinese People

The Effect of Renal Clearance on Serum Trough Concentration of Vancomycin in Elderly Patients with Severe Pneumonia